AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15195855 — intervention group
Group type: COMPARATOR
Intervention: Standard reference preparation
Number of subjects: 12
Study 12494116 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI)
Number of subjects: 0
Study 9798440 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU nasal salmon calcitonin (sCT)
Number of subjects: 21
Study 9798440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8598260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg orally every 8 hours)
Number of subjects: 51
Study 2758767 — intervention group
Group type: EXPERIMENTAL
Intervention: 250HD3 (35 mcg/day for 25 days/month)
Number of subjects: 24
Study 2758767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2758767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 337983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 15 mg
Number of subjects: 100
Study 337983 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 50 mg
Number of subjects: 100
Study 337983 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 100
Study 337983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 30 mg
Number of subjects: 100
Study 337983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 100
Study 337983 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 100
Study 337983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 100
Study 30543350 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy (CN) followed by sunitinib therapy
Number of subjects: 99
Study 30543350 — intervention group
Group type: COMPARATOR
Intervention: Deferred CN after 3 cycles of sunitinib therapy
Number of subjects: 99
Study 30543350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib therapy
Number of subjects: 99
Study 30543350 — intervention group
Group type: COMPARATOR
Intervention: Immediate CN
Number of subjects: 99
Study 30543350 — intervention group
Group type: COMPARATOR
Intervention: Deferred CN
Number of subjects: 99
Study 27213285 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 52
Study 27213285 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 52
Study 26622035 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety culture questionnaire with a complementary workshop
Number of subjects: 30
Study 26622035 — intervention group
Group type: COMPARATOR
Intervention: Safety culture questionnaire alone
Number of subjects: 30
Study 23384799 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) delivering 55 Gy in 20 fractions
Number of subjects: 216
Study 23384799 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) followed by high dose rate (HDR) brachytherapy of 2 × 8.5 Gy
Number of subjects: 216
Study 21373871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed diet with sprint training
Number of subjects: 20
Study 21373871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet with sprint training
Number of subjects: 20
Study 21373871 — intervention group
Group type: COMPARATOR
Intervention: Both groups (mixed and vegetarian diet) with sprint training
Number of subjects: 20
Study 18985628 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 25
Study 18985628 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 30 mg (positive control)
Number of subjects: 25
Study 18985628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17894827 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2838
Study 17894827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 15319390 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(dim)CD16(+)CD69(+) NK cells count >1.0 x 10(6)/l
Number of subjects: 138
Study 15319390 — intervention group
Group type: COMPARATOR
Intervention: CD56(dim)CD16(+)CD69(+) NK cells count <1.0 x 10(6)/l
Number of subjects: 138
Study 15319390 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful ongoing pregnancy
Number of subjects: 138
Study 15319390 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed pregnancy
Number of subjects: 138
Study 11417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 220
Study 11417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 220
Study 11417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (radiotherapy, tamoxifen)
Number of subjects: 220
Study 11417983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic nipple to lesion distance <40 mm
Number of subjects: 220
Study 11417983 — intervention group
Group type: EXPERIMENTAL
Intervention: High/intermediate nuclear grade
Number of subjects: 220
Study 10168033 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood progenitor-cell transplantation (PBPCT)
Number of subjects: 129
Study 10168033 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 129
Study 8485272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 12
Study 8485272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 12
Study 8485272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8485272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg and 60 mg
Number of subjects: 12
Study 3687892 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone for 2 days
Number of subjects: 0
Study 3687892 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone
Number of subjects: 0
Study 3687892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30213452 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab monotherapy (1 mg/kg, 3 mg/kg, 10 mg/kg, and 200 mg every 2 weeks)
Number of subjects: 93
Study 30213452 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg (day 1), gemcitabine 1 g/m2 (days 1 and 8), and cisplatin 80 mg/m2 (day 1) every 3 weeks followed by camrelizumab 200 mg maintenance once every 3 weeks
Number of subjects: 93
Study 26548879 — intervention group
Group type: COMPARATOR
Intervention: 3 daily denture brushings using water at ambient temperature
Number of subjects: 20
Study 26548879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily denture brushings using water at ambient temperature plus coconut soap
Number of subjects: 20
Study 26548879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily denture brushings using water at ambient temperature plus dentifrice
Number of subjects: 20
Study 26548879 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 daily denture brushings using water at ambient temperature combined with immersion in sodium perborate solution for 5 minutes before nocturnal sleep
Number of subjects: 20
Study 24573942 — intervention group
Group type: EXPERIMENTAL
Intervention: Addison's disease patients
Number of subjects: 27
Study 24573942 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 24573942 — intervention group
Group type: EXPERIMENTAL
Intervention: Addison's disease patients with longer duration of illness
Number of subjects: 27
Study 21752570 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative statement plus graphic element (speedometer metaphor or pictograph)
Number of subjects: 182
Study 21752570 — intervention group
Group type: COMPARATOR
Intervention: Narrative statement alone
Number of subjects: 182
Study 20382273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=1464)
Number of subjects: 2839
Study 20382273 — intervention group
Group type: COMPARATOR
Intervention: Non-Intervention group (N=372)
Number of subjects: 2839
Study 20382273 — intervention group
Group type: COMPARATOR
Intervention: No Risk Factors group (N=1003)
Number of subjects: 2839
Study 17908705 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐CPAP
Number of subjects: 52
Study 17908705 — intervention group
Group type: COMPARATOR
Intervention: n‐IPPV
Number of subjects: 52
Study 16051891 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 39
Study 16051891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12103384 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB (off-pump coronary artery bypass)
Number of subjects: 40
Study 12103384 — intervention group
Group type: COMPARATOR
Intervention: ONCAB (on-pump coronary artery bypass)
Number of subjects: 40
Study 11072391 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care provider prompting intervention with tailored print communications
Number of subjects: 160
Study 11072391 — intervention group
Group type: COMPARATOR
Intervention: Health care provider prompting intervention alone
Number of subjects: 160
Study 11072391 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care provider prompting intervention with tailored print communications and tailored telephone counseling
Number of subjects: 160
Study 11072391 — intervention group
Group type: COMPARATOR
Intervention: Provider intervention alone
Number of subjects: 160
Study 7476052 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg.d-1 iron supplement, low iron diet
Number of subjects: 62
Study 7476052 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo, free choice diet
Number of subjects: 62
Study 7476052 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat supplement to achieve 15 mg.d-1 iron intake
Number of subjects: 62
Study 7476052 — intervention group
Group type: COMPARATOR
Intervention: Control, free choice diet
Number of subjects: 62
Study 1417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg tablet administered orally once at 2 hrs prior to cisplatin administration.
Number of subjects: 85
Study 1417014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose tablet) administered orally once at 2 hrs prior to cisplatin administration.
Number of subjects: 85
Study 1417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication with ondansetron injection if satisfactory anti-emetic effects were not obtained.
Number of subjects: 85
Study 1417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication with ondansetron injection.
Number of subjects: 85
Study 1417014 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects observed after rescue medication with ondansetron injection.
Number of subjects: 85
Study 3886743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 83
Study 3886743 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 83
Study 30410934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% Chlorhexidine gel (Plak ®Gel; Polifarma Wellness Srl, Rome, Italy)
Number of subjects: 32
Study 30410934 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (Placebo, Polifarma Wellness Srl, Rome, Italy)
Number of subjects: 32
Study 27082008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention designed to improve medication adherence and pain-related outcomes
Number of subjects: 110
Study 27082008 — intervention group
Group type: COMPARATOR
Intervention: Provider assessments using the Aberrant Behavior Checklist (ABC)
Number of subjects: 110
Study 27082008 — intervention group
Group type: COMPARATOR
Intervention: Provider reports of AMTB
Number of subjects: 110
Study 27082008 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC ratings of experienced providers (nurse practitioners/attending physicians)
Number of subjects: 110
Study 27082008 — intervention group
Group type: COMPARATOR
Intervention: Associations between patient‐ and provider‐reported AMTB and urine drug screening results
Number of subjects: 110
Study 26282661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Therapy (CT)
Number of subjects: 1218
Study 26282661 — intervention group
Group type: COMPARATOR
Intervention: Fixed Duration Therapy (FDT)
Number of subjects: 1218
Study 24148851 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid prior to specialist consultation
Number of subjects: 80
Study 24148851 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 21160317 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection with a new, curved multifire stapler (TRANSTAR group)
Number of subjects: 100
Study 21160317 — intervention group
Group type: COMPARATOR
Intervention: Stapled transanal rectal resection with 2 traditional circular staplers (STARR group)
Number of subjects: 100
Study 18362294 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (3 mug)
Number of subjects: 14
Study 18362294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v. saline)
Number of subjects: 14
Study 17027729 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-artery stenting (n=605)
Number of subjects: 1200
Study 17027729 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (n=595)
Number of subjects: 1200
Study 12802619 — intervention group
Group type: EXPERIMENTAL
Intervention: high trans‐scrotal skin‐crease incision
Number of subjects: 256
Study 12802619 — intervention group
Group type: COMPARATOR
Intervention: suprapubic transverse inguinal incisions
Number of subjects: 256
Study 10753980 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA (alteplase) 0.9 mg/kg IV over 1 hour
Number of subjects: 142
Study 10753980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 7796857 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 12
Study 7796857 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Number of subjects: 12
Study 7796857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2162437 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP (cyclophosphamide, vincristine, methotrexate, procarbazine)
Number of subjects: 183
Study 2162437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic alternating chemotherapy (CT) of COMP and VAN (etoposide, adriamycin, nimustine)
Number of subjects: 183
Study 2162437 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus RT of 40 Gy
Number of subjects: 183
Study 2162437 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-PVP hybrid chemotherapy (CTX, ADM, VCR on day 1; cisplatin on day 8; VP-16 on days 8 and 9)
Number of subjects: 183
Study 396651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (25 mg three times per day for 1 week followed by 25 mg two times per day for 3 weeks)
Number of subjects: 84
Study 396651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 396651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 84
Study 31511288 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 170
Study 31511288 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone plus prednisolone (AAP)
Number of subjects: 170
Study 27906770 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in a simple classification for proximal humeral fractures
Number of subjects: 185
Study 27906770 — intervention group
Group type: COMPARATOR
Intervention: No training in a simple classification for proximal humeral fractures
Number of subjects: 185
Study 26255794 — intervention group
Group type: EXPERIMENTAL
Intervention: High BX diet
Number of subjects: 19
Study 26255794 — intervention group
Group type: COMPARATOR
Intervention: Low BX diet
Number of subjects: 19
Study 23073216 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exercise bout (brisk walking at 60% of peak oxygen consumption for 123 ± 18 min, net energy expenditure of 2.06 ± 0.39 MJ, ∼500 kcal)
Number of subjects: 11
Study 23073216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction of 2.10 ± 0.41 MJ
Number of subjects: 11
Study 23073216 — intervention group
Group type: COMPARATOR
Intervention: Control day of isocaloric feeding and rest (zero energy balance)
Number of subjects: 11
Study 21299475 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg orally, 4 times daily for 14 days
Number of subjects: 119
Study 21299475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 21299475 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 119
Study 18564334 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (6.25-25 mg twice daily)
Number of subjects: 1235
Study 18564334 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate (50-200 mg twice daily)
Number of subjects: 1235
Study 16820580 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (40% dextrose, K+ 100 mmol.L(‐1), insulin 70 u.L(‐1)) administered at 0.75 mL.kg(‐1) h(‐1) from start of operation until 6 hours after removal of aortic cross-clamp (AXC)
Number of subjects: 440
Study 16820580 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (0.8 microg.kg(‐1) followed by 0.113 microg.kg(‐1) h(‐1)) administered for a 6-hour period from removal of AXC
Number of subjects: 440
Study 16820580 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK+T3
Number of subjects: 440
Study 16820580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 440
Study 12603364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with suspected sleep apnoea syndrome (n = 421)
Number of subjects: 421
Study 12603364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with confirmed obstructive sleep apnoea syndrome
Number of subjects: 421
Study 12603364 — intervention group
Group type: COMPARATOR
Intervention: General population (n = 41,340)
Number of subjects: 421
Study 10839875 — intervention group
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 69
Study 10839875 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 69
Study 9103126 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC transplantation
Number of subjects: 129
Study 9103126 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 129
Study 8488694 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 0
Study 2442417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosanpolysulfate (Elmiron) 100 mg, 3 times daily for a minimum of 4 months
Number of subjects: 62
Study 2442417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosanpolysulfate (Elmiron)
Number of subjects: 62
Study 2442417 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 62
Study 30250631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvalved Spacers (NVS)
Number of subjects: 46
Study 30250631 — intervention group
Group type: COMPARATOR
Intervention: Valved Holding Chambers (VHC)
Number of subjects: 46
Study 27550746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive attention training condition
Number of subjects: 76
Study 27550746 — intervention group
Group type: COMPARATOR
Intervention: Nonadaptive control condition
Number of subjects: 76
Study 26666981 — intervention group
Group type: EXPERIMENTAL
Intervention: iCup (disposable vacuum extraction cup)
Number of subjects: 668
Study 26666981 — intervention group
Group type: COMPARATOR
Intervention: Drapier-Faure metallic cup (control)
Number of subjects: 668
Study 23129412 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (450 mg/d)
Number of subjects: 21
Study 23129412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23129412 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 21
Study 20118767 — intervention group
Group type: EXPERIMENTAL
Intervention: M. vaccae
Number of subjects: 2013
Study 20118767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study 18817987 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphurous thermal water inhalations
Number of subjects: 100
Study 18817987 — intervention group
Group type: COMPARATOR
Intervention: physiological solution
Number of subjects: 100
Study 17058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection before CPB
Number of subjects: 90
Study 17058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection after CPB
Number of subjects: 90
Study 17058823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Shenfu Injection)
Number of subjects: 90
Study 12730149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of saline for 20 minutes
Number of subjects: 7
Study 12730149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of saline
Number of subjects: 7
Study 10391422 — intervention group
Group type: EXPERIMENTAL
Intervention: oral microemulsion CsA 5 mg/kg
Number of subjects: 11
Study 10391422 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous CsA 1.5 mg/kg
Number of subjects: 11
Study 8871363 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback
Number of subjects: 0
Study 8871363 — intervention group
Group type: COMPARATOR
Intervention: No video feedback (control)
Number of subjects: 0
Study 1642943 — intervention group
Group type: COMPARATOR
Intervention: No supplementary oxygen before LMA placement
Number of subjects: 87
Study 1642943 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation with 100% oxygen after induction
Number of subjects: 87
Study 1642943 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial denitrogenation by breathing oxygen from the start of injection of the induction agent
Number of subjects: 87
Study 1642943 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal denitrogenation by breathing oxygen for 3 min
Number of subjects: 87
Study 1642943 — intervention group
Group type: EXPERIMENTAL
Intervention: Five tidal volume breaths of oxygen by face mask using positive pressure immediately after induction
Number of subjects: 87
Study 6377970 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein 600 K.U. daily for 3 months
Number of subjects: 30
Study 6377970 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 30
Study 30917531 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 100,000 IU soft capsule (Group 1)
Number of subjects: 53